Thiothixene
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Thiothixene
- Thiothixene: From Antipsychotic Therapy to Retinal Dystrophy With or Without Extraocular Anomalies
Thiothixene: From Antipsychotic Therapy to Retinal Dystrophy With or Without Extraocular Anomalies
One-Sentence Summary
Thiothixene is a typical (thioxanthene-class) antipsychotic that is currently marketed in the United States as an oral capsule. The TxGNN model predicts it may be effective for retinal dystrophy with or without extraocular anomalies, but there are currently 0 clinical trials and 0 publications supporting this specific prediction. The prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not listed in the provided US label data (thiothixene is a typical antipsychotic) |
| Predicted New Indication | Retinal dystrophy with or without extraocular anomalies |
| TxGNN Prediction Score | 99.99% (model rank 397) |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 13 (all generic ANDA listings) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the source record. Thiothixene is known as a thioxanthene-class antipsychotic that blocks dopamine D2 receptors.
No plausible mechanistic link has been identified between D2 receptor antagonism and retinal dystrophy. Retinal dystrophies are typically inherited degenerative conditions, and nothing in the available data suggests that dopamine receptor blockade would slow or reverse them. The high TxGNN score (99.99%) is a model output based on knowledge-graph patterns, and no trial or publication backs it.
This prediction should therefore be treated as a computational hypothesis, not as a supported repurposing candidate.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ANDA211642 | Thiothixene (ANI Pharmaceuticals, Inc.) | Capsule | Not provided in source data |
| ANDA215456 | Thiothixene (Amneal Pharmaceuticals NY LLC) | Capsule | Not provided in source data |
| ANDA211642 | Thiothixene (Golden State Medical Supply, Inc.) | Capsule | Not provided in source data |
| ANDA211642 | Thiothixene (Coupler LLC) | Capsule | Not provided in source data |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication has no registered trials, no literature and no identifiable mechanistic link, so it is supported only by the model score (Evidence Level L5).
To proceed, the following is needed:
- Package insert warnings and contraindications, to complete the safety screening
- Detailed mechanism-of-action data from DrugBank, to test whether any biological link to retinal disease exists
- A mechanistic or preclinical rationale showing why a D2 antagonist would affect retinal degeneration
Other predicted indications: Of the 10 predictions in this pack, only rank 10, manic bipolar affective disorder (score 99.95%), has any supporting literature. It is graded L3 and recommended as a “Research Question”. Its 20 reported publications include older head-to-head comparisons in mania or agitation (thiothixene vs chlorpromazine, loxapine and haloperidol, 1968–1988). Their design could not be verified, so they are not counted as Phase 3 RCT evidence. If the team wants to prioritize, this indication is the more evidence-supported direction. Other literature reports case-level safety signals (priapism, black hairy tongue).
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.